These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 33389461)

  • 21. A phase 3b, multicenter, open-label, single-arm study of roxadustat within a US dialysis organization: The DENALI study.
    Larkin J; Hymes J; Britton ML; Oluwatosin Y; Nolen J; Zhu L; Silva A
    Hemodial Int; 2024 Jan; 28(1):59-71. PubMed ID: 37875459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Roxadustat for the treatment of anemia in patients with chronic kidney diseases: a meta-analysis.
    Zhang L; Hou J; Li J; Su SS; Xue S
    Aging (Albany NY); 2021 Jun; 13(13):17914-17929. PubMed ID: 34115611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies.
    Akizawa T; Ueno M; Shiga T; Reusch M
    Ther Apher Dial; 2020 Dec; 24(6):628-641. PubMed ID: 31891449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of C-reactive protein on the effect of Roxadustat for the treatment of anemia in chronic kidney disease: a systematic review of randomized controlled trials.
    Luo X; Li G; Yang H; Chen L; Gao Y; Cong J; Luo H; Zhang W
    BMC Nephrol; 2024 Feb; 25(1):47. PubMed ID: 38311719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients.
    Besarab A; Chernyavskaya E; Motylev I; Shutov E; Kumbar LM; Gurevich K; Chan DT; Leong R; Poole L; Zhong M; Saikali KG; Franco M; Hemmerich S; Yu KH; Neff TB
    J Am Soc Nephrol; 2016 Apr; 27(4):1225-33. PubMed ID: 26494833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase 3b, multicenter, open-label, single-arm study of roxadustat (ASPEN): Operational learnings within United States dialysis organizations.
    Fishbane S; Vishnepolsky M; Oluwatosin Y; Nolen J; Zhu L; Cooper K; Young A
    Hemodial Int; 2023 Oct; 27(4):400-410. PubMed ID: 37380364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Roxadustat regulates iron metabolism in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A meta-analysis.
    Hou YP; Wang C; Mao XY; Zhang MZ; Li B
    J Formos Med Assoc; 2022 Nov; 121(11):2288-2299. PubMed ID: 35871036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Roxadustat in Patients with Chronic Kidney Disease: An Updated Meta-Analysis of Randomized Controlled Trials including 6,518 Patients.
    Lei J; Li H; Wang S
    Biomed Res Int; 2022; 2022():2413176. PubMed ID: 36420092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study.
    Fishbane S; Pollock CA; El-Shahawy M; Escudero ET; Rastogi A; Van BP; Frison L; Houser M; Pola M; Little DJ; Guzman N; Pergola PE
    J Am Soc Nephrol; 2022 Apr; 33(4):850-866. PubMed ID: 35361724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Roxadustat treatment for anemia in peritoneal dialysis patients: A randomized controlled trial.
    Hou YP; Mao XY; Wang C; Xu ZH; Bu ZH; Xu M; Li B
    J Formos Med Assoc; 2022 Feb; 121(2):529-538. PubMed ID: 34167878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An evaluation of roxadustat for the treatment of anemia associated with chronic kidney disease.
    Kurata Y; Tanaka T; Nangaku M
    Expert Opin Pharmacother; 2022 Jan; 23(1):19-28. PubMed ID: 34686069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and safety of roxadustat in the treatment of anemia of kidney disease: a systematic review and meta-analysis.
    Wang H; Huang K; Wang C; Chen C; Fang H; Cao J
    Ann Palliat Med; 2021 Apr; 10(4):4736-4746. PubMed ID: 33966423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in Iron Availability with Roxadustat in Nondialysis- and Dialysis-Dependent Patients with Anemia of CKD.
    Pergola PE; Charytan C; Little DJ; Tham S; Szczech L; Leong R; Fishbane S
    Kidney360; 2022 Sep; 3(9):1511-1528. PubMed ID: 36245647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.
    Provenzano R; Tumlin J; Zabaneh R; Chou J; Hemmerich S; Neff TB; Yu KP
    J Clin Pharmacol; 2020 Nov; 60(11):1432-1440. PubMed ID: 32603526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease.
    Chen J; Shou X; Xu Y; Jin L; Zhu C; Ye X; Mei Z; Chen P
    Aging (Albany NY); 2023 Mar; 15(6):2237-2274. PubMed ID: 36988549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Four Global Roxadustat Phase 3 Trials.
    Hamano T; Yamaguchi Y; Goto K; Martin S; Jiletcovici A; Dellanna F; Akizawa T; Barratt J
    Adv Ther; 2024 Apr; 41(4):1553-1575. PubMed ID: 38363466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Efficacy and Safety of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis.
    Wang L; Yin H; Yang L; Zhang F; Wang S; Liao D
    Front Pharmacol; 2022; 13():779694. PubMed ID: 35559232
    [No Abstract]   [Full Text] [Related]  

  • 38. The efficacy and economic evaluation of roxadustat treatment for anemia in patients with kidney disease not receiving dialysis.
    Hu Z; Tao H; Shi A; Pan J
    Expert Rev Pharmacoecon Outcomes Res; 2020 Aug; 20(4):411-418. PubMed ID: 32249625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Roxadustat in the treatment of anaemia in chronic kidney disease.
    Del Vecchio L; Locatelli F
    Expert Opin Investig Drugs; 2018 Jan; 27(1):125-133. PubMed ID: 29254377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Phase 3 Roxadustat Trials in Japan.
    Hamano T; Yamaguchi Y; Goto K; Mizokawa S; Ito Y; Dellanna F; Barratt J; Akizawa T
    Adv Ther; 2024 Apr; 41(4):1526-1552. PubMed ID: 38363463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.